Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — |
| R&D | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$2.8K | −$425.0K | −$842.0K | −$611.0K | −$347.3K |
| EBITDA | −$2.8K | −$425.0K | −$842.0K | −$611.0K | −$347.3K |
| Net income | −$2.8K | $2.4M | $5.4M | $155.1K | −$224.5K |
| Net margin | — | — | — | — | — |
| EPS (diluted) | -0.00 | 0.24 | 0.61 | 0.02 | -0.06 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds ASCBU.
No tracked institution reports a position in ASCBU as of their last filing.
No one on the platform has traded ASCBU yet.
| -12.34% |
| $22M |
| — |
| ESLAEstrella Immunopharma, Inc. | $1.03 | +4.80% | $44M | — |
| GBRGGoldenbridge Acquisition Limited | $6.11 | -13.71% | $22M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.